The first study included a total of 320 patients whose disease was in the ‘ chronic phase’, three quarters of whom had stopped responding to imatinib.
Esimeses uuringus osales kokku 320 patsienti, kelle haigus oli kroonilises faasis; nendest kolmel neljandikul ei tekkinud enam imatiniibiga ravivastust.